Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
Publication
, Journal Article
Hamid, O; Puzanov, I; Dummer, R; Schachter, J; Daud, A; Schadendorf, D; Blank, C; Cranmer, LD; Robert, C; Pavlick, AC; Gonzalez, R; Hodi, FS ...
Published in: Annals of Oncology
October 1, 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi379
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Hamid, O., Puzanov, I., Dummer, R., Schachter, J., Daud, A., Schadendorf, D., … Ribas, A. (2016). Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology, 27, vi379. https://doi.org/10.1093/annonc/mdw379.02
Hamid, O., I. Puzanov, R. Dummer, J. Schachter, A. Daud, D. Schadendorf, C. Blank, et al. “Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma.” Annals of Oncology 27 (October 1, 2016): vi379. https://doi.org/10.1093/annonc/mdw379.02.
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology. 2016 Oct 1;27:vi379.
Hamid, O., et al. “Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma.” Annals of Oncology, vol. 27, Oct. 2016, p. vi379. Scopus, doi:10.1093/annonc/mdw379.02.
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama A, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus SW, Ibrahim N, Ribas A. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology. 2016 Oct 1;27:vi379.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi379
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis